Project Grant R44EY028484

This $745,607 Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) supports the development of the RETIVUE ENTIREEYE, a handheld, high-resolution, non-contact, single-image, widefield retinal screening camera for premature and healthy newborn babies. The device utilizes a novel all-digital, no moving parts scanning light module to capture a seamless, high-quality, diagnostic ultra-widefield image of the entire baby eye in a single shot. This technology has the...

This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), is providing $306,462 to Ifocus Imaging LLC to develop a software platform called OCT-ART-DR. The platform will automate the diagnosis and staging of diabetic retinopathy using optical coherence tomography angiography (OCTA) imaging and artificial intelligence. The key products to be delivered under this award include: 1) Improved AI-based segmentation of OCTA image...

This Project Grant award from the National Eye Institute's Vision Research program (CFDA 93.867) provides funding of $179,440 to Kennesaw State University to develop an innovative smartphone-based retinal imaging system and deep learning algorithms for detecting diabetic retinopathy in Egypt. The two-phase project aims to create a portable and cost-effective retinal imaging solution that can enhance access to screening for this serious diabetes complication, which can lead to vision loss without...

The National Eye Institute (NEI) awarded Kineolabs, Inc. a $300,001 Project Grant under the Vision Research program (CFDA 93.867) to develop a portable, low-cost line-scan swept-source optical coherence tomography (LS-SS-OCT) imaging system. The objective is to use this LS-SS-OCT technology for early detection and monitoring of age-related macular degeneration (AMD), diabetic retinopathy, and other eye diseases. The project aims to make OCT imaging more affordable and accessible to reduce the...

This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop and validate a novel Adaptive Optics Optical Coherence Tomography (AO-OCT) system tailored for high-resolution, wide-field retinal imaging in small animal models, specifically mice. The $305,000 project, awarded on September 1, 2025, with an expected completion date of August 31, 2026, has two key objectives: Develop and optimize a portable AO-OCT system with enhanced imaging capabilities...

The National Eye Institute (NEI) awarded a $256,296 Project Grant (CFDA 93.867 - Vision Research) to The General Hospital Corporation (Massachusetts General Hospital) to develop new "Auto-Sensing, Instantaneous Adaptive Ranging Optical Coherence Tomography (OCTA)" technology. This technology aims to expand the imaging depth range of OCTA systems, enabling improved visualization of the critical peripheral retinal microvasculature. The project will leverage advances in integrated...

The National Eye Institute (NEI) awarded a Project Grant of $305,853 to Bluebird Photonics, Inc. under the Vision Research federal grant program (CFDA 93.867) to develop a novel light source for robust multi-MHz retinal optical coherence tomography (OCT). The project aims to enable next-generation OCT technology that can provide diagnostic screening and visualization of both the central and peripheral retinal areas through a roughly 50-fold increase in imaging speed. This advancement is...

This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) supports the development of a novel, noninvasive, and sensitive diagnostic method to measure retinal dysfunction. The $491,466 award will fund research at the University of California, San Francisco (UCSF) from January 1, 2025 to December 31, 2026. The project aims to create a scalable diagnostic tool that can detect the earliest signs of retinal diseases like diabetic retinopathy and retinitis pigmentosa,...

The National Eye Institute (NEI), under the Department of Health and Human Services, awarded a $358,065 Project Grant to Revel Pharmaceuticals Inc., a biotechnology company in San Francisco, California. The grant is part of the NEI's Vision Research program (CFDA 93.867), which supports research to understand, prevent, and treat vision-related conditions and diseases. The goal of this Phase I grant is for Revel Pharmaceuticals to optimize lead drug candidates and demonstrate the activity of...

This Project Grant award from the National Eye Institute (NEI), part of the U.S. Department of Health and Human Services, aims to advance understanding of the molecular and cellular mechanisms underlying diabetic retinopathy (DR) and diabetic macular edema (DME). The $1,786,652 award, granted on September 15, 2025, supports the application of the "TEMPO" proteomic platform to identify protein biomarker signatures and key cellular drivers of DR stages and DME using human liquid biopsy...